Oramed Pharmaceuticals Inc. (ORMP) financial statements (2022 and earlier)

Company profile

Business Address 1185 AVENUE OF THE AMERICAS, 3RD FLOOR
NEW YORK, NY 10036
State of Incorp. DE
Fiscal Year End August 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

11/30/2021
TTM
8/31/2021
8/31/2020
8/31/2019
8/31/2018
8/31/2017
8/31/2016
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments39,45383,09622,5947,0309,5886,8296,762
Cash and cash equivalents31,88077,24519,2963,3294,9963,9693,907
Short-term investments7,5735,8513,2983,7014,5922,8602,855
Restricted cash and investments     1616
Deposits current assets111,08211,04411,06025,25220,87513,29324,254
Other undisclosed current assets1,7971,1976,8571,042574159198
Total current assets:152,33295,33740,51133,32431,03720,29731,230
Noncurrent Assets
Operating lease, right-of-use asset50453375 
Property, plant and equipment3853979924171816
Long-term investments and receivables4,13119,2353,9281,2955,57011
Long-term investments4,13119,2353,9281,2955,57011
Prepaid pension costs11
Other undisclosed noncurrent assets25,09812,497202010,77318,39611,572
Total noncurrent assets:30,11832,6624,1221,33916,36018,41511,600
TOTAL ASSETS:182,450127,99944,63334,66347,39738,71242,830
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:4,7613,7921,6992,5412,0582,7161,411
Other undisclosed accounts payable and accrued liabilities4,7613,7921,6992,5412,0582,7161,411
Deferred revenue  2,7032,703
Due to related parties6654906446 48
Deferred revenue and credits2,4492,162
Other liabilities207      
Other undisclosed current liabilities2,6262,83344 2,449  
Total current liabilities:7,6606,6794,5365,3084,5535,1653,621
Noncurrent Liabilities
Long-term debt and lease obligation37440331    
Operating lease, liability37440331 
Liabilities, other than long-term debt, including:3,5704,2447,1879,96234414,30913,019
Deferred revenue and credits13,83712,604
Accounts payable and accrued liabilities 823     
Deferred revenue3,570 6,9479,658
Liability for uncertainty in income taxes  1111111111
Liability, pension and other postretirement and postemployment benefits  1822201814
Other liabilities  211271313443390
Other undisclosed liabilities, other than long-term debt 3,421     
Other undisclosed noncurrent liabilities155156  11,388  
Total noncurrent liabilities:4,0994,8037,2189,96211,73214,30913,019
Total liabilities:11,75911,48211,75415,27016,28519,47416,640
Stockholders' equity
Stockholders' equity attributable to parent170,155115,77332,87919,39331,11219,23826,190
Common stock458424284208207163157
Additional paid in capital292,439230,201125,209100,28899,42675,17071,943
Accumulated other comprehensive income    702401106
Accumulated deficit(122,742)(114,852)(92,614)(81,103)(69,223)(56,496)(46,016)
Stockholders' equity attributable to noncontrolling interest536744     
Total stockholders' equity:170,691116,51732,87919,39331,11219,23826,190
TOTAL LIABILITIES AND EQUITY:182,450127,99944,63334,66347,39738,71242,830

Income statement (P&L) ($ in thousands)

11/30/2021
TTM
8/31/2021
8/31/2020
8/31/2019
8/31/2018
8/31/2017
8/31/2016
Revenues2,7032,7032,7102,7032,4492,456641
Revenue, net2,1942,194
Cost of revenue   (90) (187)(490)
Gross profit:2,7032,7032,7102,6132,4492,269151
Operating expenses(20,425)(26,926)(14,467)(17,244)(16,062)(13,040)(10,161)
Other undisclosed operating income (loss)(8,734)   86  
Operating loss:(26,456)(24,223)(11,757)(14,631)(13,527)(10,771)(10,010)
Nonoperating income (expense)273(195)246576800691381
Foreign currency transaction gain (loss), before tax383(187)     
Other nonoperating income (expense)85(8)246576800691381
Loss from continuing operations before equity method investments, income taxes:(26,183)(24,418)(11,511)(14,055)(12,727)(10,080)(9,629)
Other undisclosed loss from continuing operations before income taxes(517)      
Loss from continuing operations before income taxes:(26,700)(24,418)(11,511)(14,055)(12,727)(10,080)(9,629)
Income tax expense   (300) (400)(1,335)
Loss before gain (loss) on sale of properties:(26,700)(24,418)(11,511)(14,355)(12,727)(10,480)(10,964)
Other undisclosed net income1,1831,429     
Net loss:(25,517)(22,989)(11,511)(14,355)(12,727)(10,480)(10,964)
Net income attributable to noncontrolling interest20,95120,743     
Other undisclosed net loss attributable to parent(20,951)(20,743)     
Net loss attributable to parent:(25,517)(22,989)(11,511)(14,355)(12,727)(10,480)(10,964)
Other undisclosed net income available to common stockholders, basic46,18645,978     
Net income (loss) available to common stockholders, diluted:20,66922,989(11,511)(14,355)(12,727)(10,480)(10,964)

Comprehensive Income ($ in thousands)

11/30/2021
TTM
8/31/2021
8/31/2020
8/31/2019
8/31/2018
8/31/2017
8/31/2016
Net loss:(25,517)(22,989)(11,511)(14,355)(12,727)(10,480)(10,964)
Other comprehensive income (loss)    301295(452)
Comprehensive loss:(25,517)(22,989)(11,511)(14,355)(12,426)(10,185)(11,416)
Comprehensive income, net of tax, attributable to noncontrolling interest959751     
Other undisclosed comprehensive income, net of tax, attributable to parent44,47644,476     
Comprehensive income (loss), net of tax, attributable to parent:19,91822,238(11,511)(14,355)(12,426)(10,185)(11,416)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: